P
Pavel Hala
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 39
Citations - 679
Pavel Hala is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Atrial fibrillation. The author has an hindex of 10, co-authored 25 publications receiving 374 citations.
Papers
More filters
Journal ArticleDOI
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
Pavel Osmancik,Dalibor Herman,Petr Neuzil,Pavel Hala,Milos Taborsky,Petr Kala,Martin Poloczek,Josef Stasek,Ludek Haman,Marian Branny,Jan Chovančík,Pavel Červinka,Jiri Holy,Tomas Kovarnik,David Zemánek,Stepan Havranek,Vlastimil Vančura,Jan Opatrny,Petr Peichl,Petr Tousek,Veronika Lekesova,Jiri Jarkovsky,Martina Novackova,Klára Benešová,Petr Widimsky,Vivek Y. Reddy,Prague Trial Investigators +26 more
TL;DR: Among patients at high risk for stroke and increased risk of bleeding, LAAC was noninferior to DOAC in preventing major AF-related cardiovascular, neurological, and bleeding events.
Journal ArticleDOI
Increasing venoarterial extracorporeal membrane oxygenation flow negatively affects left ventricular performance in a porcine model of cardiogenic shock
Petr Ostadal,Mikulas Mlcek,Andreas Krüger,Pavel Hala,Stanislav Lacko,Martin Mates,Dagmar Vondrakova,Tomas Svoboda,Matej Hrachovina,Marek Janotka,Hana Psotova,Svitlana Strunina,Otomar Kittnar,Petr Neuzil +13 more
TL;DR: It appears that to mitigate negative effects on LV function, optimal VA ECMO blood flow should be set as low as possible to allow adequate tissue perfusion.
Journal ArticleDOI
Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
Pavel Osmancik,Petr Tousek,Dalibor Herman,Petr Neuzil,Pavel Hala,Josef Stasek,Ludek Haman,Petr Kala,Martin Poloczek,Marian Branny,Jan Chovančík,Pavel Červinka,Jiri Holy,Vlastimil Vančura,Richard Rokyta,Milos Taborsky,Tomas Kovarnik,David Zemánek,Petr Peichl,Sarka Haskova,Jiri Jarkovsky,Petr Widimsky +21 more
TL;DR: The PRAGUE‐17 trial will determine if LAA occlusion is noninferior to treatment with NOAC in moderate‐ to high‐risk AF patients and any of the following events within 24 months after randomization.
Journal ArticleDOI
Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation
Dinesh Sharma,Vivek Y. Reddy,Marcus Sandri,Philipp Schulz,Nicolas Majunke,Pavel Hala,Jens Wiebe,Tomas Mraz,Marc A. Miller,Petr Neuzil,Sven Möbius-Winkler,Horst Sievert,Peter Sick +12 more
TL;DR: The PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device) trials revealed.
Journal ArticleDOI
Anatomical predictors for successful pulmonary vein isolation using balloon-based technologies in atrial fibrillation
Alexey Tsyganov,Jan Petru,Jan Skoda,Lucie Sediva,Pavel Hala,Jiri Weichet,Marek Janotka,Milan Chovanec,Petr Neuzil,Vivek Y. Reddy +9 more
TL;DR: The variability of PV anatomy did not significantly compromise acute success of PVI or patient outcomes, and there was no absolute cutoff between PV anatomy and clinical success.